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Background.Strategies aiming at minimization or elimination of systemic immunosuppression are key immediate goals for clin-
ical expansion of vascularized composite allotransplantation (VCA). We compared the in vitro and in vivo immunomodulatory effi-
cacy of adipose-derived mesenchymal stem cells (AD-MSCs) and bone marrow (BM)–derived MSCs in a rat VCA model.
Methods. Both cell types were tested in vitro for suppressor function using mixed lymphocyte reactivity assays. AD-MSCs or
BM-MSCs were administered intravenously (1  106 or 5  106 cells/animal) to Lewis rat recipients of mismatched Brown
Norway hindlimb transplants. Short course tacrolimus (FK-506) monotherapy was withdrawn at postoperative day 21. In vivo reg-
ulatory T-cell induction, peripheral blood chimerism, andmicrochimerism in lymphatic organs were analyzed.Results.AD-MSCs
and BM-MSCs exhibited strong dose-dependent suppressor function in vitro, which was significantly more pronounced for AD
cells. In vivo, all animals revealed peripheral multi-lineage chimerism at four weeks (P < 0.01) independent of cell type and dosage.
Regulatory T-cell levels were increased with both cell types, the most in AD-MSC groups. These immunomodulatory effects were
only transient. MSC treatment resulted in long-term (>120 day) allograft survival in 47% of the animals, which correlated with du-
rablemicrochimerism in BM and spleen.Conclusions.AD-MSCs and BM-MSCs exert immunomodulatory effects that prolong
survival of immunogenic skin-bearing VCA grafts with short course (21 day) tacrolimus induction therapy. The in vivo findings in
terms of allograft survival did not reflect superior immunomodulatory characteristics of AD-MSCs found in vitro.
(Transplantation 2015;99: 1765–1773)
Greater than 30 face and 100 upper extremity humanvascularized composite allotransplantation (VCA)
procedures have been performed around the world in the
past 15 years.1-3 Although recently defined as solid organ
transplantation (SOT) byUNOS, VCAare inherently different
in that they are life-enhancing rather than life-saving grafts,
with clinical success determined not only by graft survival
but also by neurofunctional outcomes.4 The chronic risks
of immunosuppression must be minimized or eliminated to
achieve equipoise in VCA and facilitate clinical expansion.
Novel cellular therapies that combine the benefits of immuno-
regulation with neuroregeneration could optimize immune,
functional, and patient quality of life outcomes of these recon-
structive modalities.5
Bone marrow (BM)–derived or adipose-derived (AD)mes-
enchymal stem cells (MSCs) have emerged as promising cell
therapies for immunomodulation.6 Compared to BM, adi-
pose tissue is a richer source of MSCs with up to 10-fold
higher cell yields.7 The AD-MSCs possess superior immuno-
modulatory and suppressor potential in vitro compared to
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BM-MSCs.8,9Mesenchymal stem cells have been successfully
used to facilitate hematopoietic stem cell engraftment,10,11 in
clinical SOT,12,13 and treatment of graft-versus-host dis-
ease.14,15 Unlike most SOT, VCA poses a stringent challenge
because of the differential antigenicity of tissues and the high
immunogenicity of skin. However, early studies in preclinical
models demonstrate that MSCs are indeed immunomodula-
tory in VCA, driving the momentum for active research ef-
forts in this area.16
We evaluated the dose-dependent suppressor effect in vitro
and immunomodulatory efficacy in vivo of BM-MSCs and
AD-MSCs in a rodent VCA model.
MATERIALS AND METHODS
All experiments were approved and performed in compli-
ance with University of Pittsburgh Institutional Animal Care
and Use Committee guidelines.
MSC Isolation
Inguinal adipose tissue was obtained from 6- to 8-week-
old Brown Norway (BN) rats and enzymatically digested
with collagenase type II (Worthington Biochemical Corp,
Lakewood,NJ) and bovine serum albumin (Millipore, Billerica,
MA) inHanks balanced saline solution (CellgroMediatech Inc.
Manassas, VA) for 60 minutes at 37 °C. After centrifugation,
the cellular pellet (stromal vascular fraction) was erythrocyte-
depleted by lysis buffer, filtered, and transferred complete
medium (Dulbecco's modified eagle’s medium/F-12, 10%
fetal bovine serum, 1% penicillin/streptomycin, 1.25 mg/L
amphotericin-B [all Gibco, Grand Island, NY], 0.1 μM dexa-
methasone [Sigma-Aldrich, St. Louis, MO]). The AD-MSCs
were allowed to attach for 6 hours, washed with phosphate-
buffered saline and expanded until passage 3.
The BM-MSCs were obtained from 6- to 8-week-old BN
rats by flushing long bones with Roswell Park Memorial In-
stitute medium 1640 (Lonza, Walkerville, MD). The cellular
pellet was erythrocyte-depleted, centrifuged, resuspended in
complete medium (Roswell ParkMemorial Institute medium
1640,10%fetal bovine serum,2.5μMHEPES [Sigma-Aldrich],
1% penicillin-streptomycin, 1.25 mg/L amphotericin B, 1%
L-glutamine, 1% sodium pyruvate, and 1%2-mercaptoethanol
[allGibco]) andexpanded invitrountil passage3. For injections,
MSCswerelifted,countedandresuspended(1106and5106
cells) in 1mL of phosphate-buffered saline for injection.
Characterization of MSC
Expanded cellswere stained forCD29,CD73,CD90,CD45,
and RT1b (MHC I) and analyzed using a fluorescence-
activated cell sorter (Aria, Becton Dickinson, Franklin Lakes,
NJ). Data were analyzed using FlowJo software (TreeStar
Inc., Ashland, OR).
Mixed Lymphocyte Reaction Assays
Responder T cells were isolated from blood, spleens, or
lymph nodes of naive rats (Lewis [LEW]), and stimulator cells
were isolated from spleens of donor rats (BN). Responder and
stimulator cell suspensions were erythrocyte-depleted by lysis
buffer. Stimulators were irradiated at 3000 rads.
Responder peripheral blood mononuclear cells (PBMCs)
were isolated fromwhole blood of naive LEW rats using gra-
dient density centrifugationmethod, whereas BNMSCswere
isolated as described above. T cells were isolated by T-cell en-
richment columns (R&D Systems, Minneapolis, MN), and
cell purity was confirmed to be greater than 90% by flow
cytometry for CD3+ cells.
In the primary suppressor assay, T-cells (2 105 cells/well)
were cocultured for 7 days with either BN AD-MSCs
or BM–MSCs (T-cell to AD-MSC/BM-MSC ratio of 1:1,
4:1, 8:1, and 16:1) in triplicates in round-bottom 96-well
plates, in the presence of irradiated naïve BN splenocytes
(5  104 cells/well).
In the secondary suppressor assay, LEW PBMCs (2  105
cells/well) were cocultured for 72 hours with BN AD-MSCs
or BM-MSCs (PBMCs to AD-MSC/BM-MSC ratio of 1:1,
2:1, 4:1 and 8:1) while stimulated with anti-CD3 and anti-
CD28 monoclonal antibodies (each 2 μg/mL).
Finally, to assess T-cell proliferation, cells in both assays
were pulsed with [3H]thymidine (1 mCi/well) for the final
8 hours and [3H]thymidine incorporation was measured as
counts per minute (CPM) in a liquid scintillation counter
(Perkin Elmer). Six experiments were performed for both
mixed lymphocyte reaction (MLR) assays.
Animals
Six- to 8-week-old male LEW (RT11, recipient) and BN
(RT1n, donor) rats weighing 250 to 300 g were purchased
from Harlan (Indianapolis, IN) and maintained in a specific
pathogen-free environment at the University of Pittsburgh.
Surgical Technique and Procedural Detail
Lewis rats received orthotopic hindlimb transplants from
BNdonor rats. Isoflurane was used for inhalation anesthesia.
Bilateral shaved hind limbs of BN donors were dissected
through a circumferential skin incision, after ligation of epi-
gastric vessels, dissection of femoral vessels, and transection
at the level of the inguinal ligament. The 2 limbs were ampu-
tated at midfemoral level and served as donor limbs for 2
LEW recipients. Osteosynthesis was performed using an
intramedullary 18-gauge needle. Sciatic nerves were coapted
using 9-0 nylon sutures (Microsurgery Instruments, Inc.,
Bellaire, TX) and the muscles sutured with interrupted 4-0
Vicryl stitches (Ethicon Inc., Somerville, NJ). Microsurgical
anastomosis of the femoral artery was performed with
interrupted 11-0 nylon stitches, whereas a polyamide tube
(RiverTech Medical, Chattanooga, TN) was used as cuff for
the femoral vein, as reported earlier.17
Experimental Protocol
Recipient animals were assigned to 5 groups: controls
(n = 5), 1  106 BM-MSCs (n = 6), 5  106 BM-MSCs
(n = 7), 1  106 AD-MSCs (n = 8), and 5  106 AD-MSCs
(n = 9). All recipients were treated with rabbit antirat lym-
phocyte serum (CEDARLANE, Burlington, NC) 4 days be-
fore and 1 day after surgery. Daily immunosuppression
with tacrolimus (FK-506; 0.5 mg/kg) was administered intra-
peritoneally from day 0 to postoperative day (POD) 21. The
treatment groups received a single-shot MSC injection intra-
venously on POD 1, injected slowly through the penile vein
using a 30-gauge needle. Animals were observed daily for
signs of rejection, assessed according to clinical VCA rejec-
tion grading which is based on graft gross appearance.18
When rejection grade III was reached (endpoint), animals
were sacrificed for tissue sampling. In 2 nonrejecting animals,
BN donor skin grafts were transplanted to the neck to con-
firm donor-specific tolerance after 120 days.
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Analysis of Regulatory T Cell and Chimerism
Chimerism and regulatory T-cell (Treg) levels were assessed
in peripheral blood on PODs 28 and 42 in MSC-treated ani-
mals (n = 14 in AD-MSC groups and n = 9 in BM-MSC
groups). As controls (n = 5) rejected early, blood tests were
only possible at 4 weeks. Peripheral blood, lymph nodes,
spleens, thymus, and BM of recipient LEW rats were col-
lected at euthanasia in long-term survivors (>120 days;
BM-MSC groups [n = 3]; AD-MSC groups [n = 6]) to analyze
microchimerism.
For Treg analysis, red blood cells were erythrocyte-depleted
and remaining cells stained with various cell surface markers
(fluorochrome-conjugated mouse anti-rat CD3, CD4, CD8,
CD25,CD11b/c,CD45RAantibodies)or intracellularmarkers
(fluorochrome-conjugatedmouse antirat Foxp3 antibody).
Peripheral blood and lymphatic tissue chimerismwas eval-
uated with mouse antirat class I RT1Ac antibodies (AbD
Serotec) were used for donor cell labeling (RT1n, BN rats)
and mouse antirat CD45Ra, CD11b/c, CD4, and CD8 anti-
bodies (eBioscience) were used as markers of cell lineages.
All cells were then analyzed using flow cytometry (LSRII)
and data analyzed using FlowJo software (TreeStar Inc.,
Ashland, OR).
Histopathology
Upon euthanasia, component tissues from recipient graft
explants were formalin-fixed and paraffin-embedded. Four-
μm sections were stained with hematoxylin-eosin, graded
by blinded pathologists based on the Banff classification,19
digitally photographed at 10 magnification and correlated
with clinical photographs of limbs at varying time points in
the rejection course.
Statistical Analysis
InStat and Prism software (GraphPad Software, La Jolla,
CA) were used for statistical analysis. The data are presented
as means ± SD unless otherwise indicated. Differences be-
tween groups were assessed by unpaired analysis of variance.
Graft survival was compared between the different groups
using log-rank (Mantel-Cox) test and represented as Kaplan-
Meier curve. A value of P less than 0.05 was considered
statistically significant.
RESULTS
Characterization of AD-MSC and BM-MSC
The MSCs from BM and adipose tissue were character-
ized using flow cytometry (Figure 1). Both cell lines were
negative for the hematopoietic marker CD45 (0.46%
for BM-MSCs [Figure 1A] and 0.48% for AD-MSCs
FIGURE 2. MLR with LEW Tcells (recipient) stimulated with BN irra-
diated splenocytes (donor). Although LEW T cells showed high
alloresponsiveness after the addition of donor cells, this was widely
suppressed in the presence of AD-MSCs. BM-MSCs showed
dose-dependent immunosuppression, which was less extensive
than with AD-MSCs. Represented in CPM.
FIGURE 1. MSCs were characterized before cell-based immunosuppressive therapy according to surface marker expression. BM-MSCs
(A) and AD-MSCs (B) showed similar expression profiles (CD29hiCD73hiCD90hiCD45low).
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[Figure 1B]). Both cell types expressed high levels of CD29
(99.7% vs 97.1%), CD90 (98.0% vs 94.3%), and CD73
(93.6% vs 90.5%).
Analysis of Suppressor Activity In Vitro by MLR Assay
High proliferation was observed when recipient (LEW)
T cells were stimulated with donor (BN) splenocytes,
(29.8 ± 3.6  103 CPM [Figure 2]). The LEW T cells and
BN splenocytes were cultured alone as negative controls,
and no proliferation was observed (data not shown). Adding
AD-MSCs to stimulated LEW T cells inhibited proliferation
(0.35 ± 0.04  103 CPM at 1:1, 0.54 ± 0.07  103 CPM
at 16:1, all P < 0.001 vs. LEW + BN). BM-MSCs showed
dose-dependent suppression: if cocultured 1:1, LEWT-cell pro-
liferation was 1.6 ± 0.2  103 CPM, increasing up to
8.8 ± 0.2  103 CPM at a 16:1 ratio (all P < 0.001 vs.
LEW + BN). The difference between AD-MSC– and
BM-MSC–related suppression was significant at both 8:1 and
16:1 ratios (P < 0.001).
In a secondary assay, PBMCs from naive animals were
highly responsive to stimulation with antibodies against
CD3/CD28 (10.7 ± 0.3 103 CPM [Figure 3]). Unstimulated
PBMCs were taken as negative control and did not prolifer-
ate (data not shown). Stimulated PBMCs (sPBMCs) were
significantly suppressed in a dose-dependent manner after
addition of AD-MSCs or BM-MSCs. At a 1:1 ratio (sPBMCs:
MSCs), values of 1.1 ± 0.03  103 CPM were obtained
for AD-MSCs (P < 0.001 vs sPBMCs), whereas suppres-
sion was less extensive for BM-MSCs at a 1:1 ratio
(2.9 ± 0.04  103 CPM, P < 0.001 vs both AD-MSCs
and sPBMCs). At an 8:1 ratio, results were 2.3 ± 0.08  103
and 3.3 ± 0.03 103 CPM for AD-MSCs and BM-MSCs, re-
spectively (P < 0.001 vs sPBMCs; P < 0.05 AD-MSCs vs
BM-MSCs).
Allograft Survival and Tolerance
Controls consistently rejected their grafts before POD 50
(P < 0.05 vs BM-MSC/AD-MSC; Figure 4A). Variation in cell
type or dosage did not correlate with significant differences in
rejection or graft survival. Eight limbs of 17 in the AD-MSC
FIGURE 3. MLR with PBMC under anti-CD3/CD28 stimulation. Al-
though stimulated PBMCs from naive animals showed an extensive
response (control [N]), MSCs were able to suppress this effect. The
immunosuppressive effect was dose-dependent and more pro-
nounced in the AD-MSC than BM-MSC groups. Represented
in CPM.
FIGURE 4. Overall allograft survival curve (A) and data (B) for AD-MSC- and BM-MSC–treated animals (n = 30). All animals received ALS con-
ditioning and immunosuppression with FK-506 from POD 0 until POD 21. Control animals (n = 5) completely rejected (grade III) the graft within
50 days, whereas cell-treated groups showed prolonged survival. Almost half (47%) of theMSC-treated animals exhibited long-term survival of
the allograft (>120 days). ALS indicates antilymphocyte serum.
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group and 6 limbs out of 13 in the BM-MSC group were
rejected by POD 60, followed by an additional allograft re-
jection in both AD-MSC and BM-MSC groups before
POD 120. Overall, 47% of the transplanted limbs survived
long-term beyond 120 days (8/17 for AD-MSC and 6/13
for BM-MSC; Figure 4B). Rejection grade in these animals
was Banff 0-1. In 2 long-term survivors (n = 1 for each
AD-MSCand BM-MSC group), secondary BN rat skin grafts
were rejected within 20 days.
Chimerism
Peripheral blood multilineage chimerism was detected
after 4 weeks in all animals treated with AD-MSCs and
BM-MSCs (Figure 5A-C). Although controls showed no chi-
merism (0.65 ± 0.72%), levels for AD-MSC/BM-MSC–
treated animals ranged between 5.06 ± 2.41 and 6.71 ± 1.52%
(P < 0.01 vs control). Results did not differ between the
groups receiving MSCs (dosage or cell type). Peripheral
blood chimerism levels decreased with time and were
0.35 ± 0.28 and 0.98 ± 1.22%by 6weeks, representing a sig-
nificant drop (P < 0.01 vs at 4 weeks in all groups). Loss of
peripheral chimerism was observed in early rejectors as well
as long-term survivors. Blood samples, lymphatic organs,
and BM were analyzed at endpoints for detection of micro-
chimerism in long-term survivors (>120 days) (Figure 6).
In the peripheral blood and thymuses of AD-MSC and
BM-MSC groups, levels were below 1%. Inguinal lymph
nodes of BM-MSC animals showed 2.79 ± 1.63% microchi-
merism on the transplanted side, whereas animals receiving
AD-MSCs showed lower levels (1.04 ± 1.14%). In the spleen,
AD-MSC animals revealed microchimerism with a percent-
age of 5.43 ± 2.09% compared to 3.00 ± 1.44% in
BM-MSC animals. Microchimerism was detected in the
tibial BM of the transplanted limb with 4.23 ± 0.72% in
the BM-MSC group and 4.74 ± 1.87% in the AD-MSC
group. Bone marrow of nontransplanted recipient tibias also
exhibited microchimerism (3.17 ± 0.26% and 3.19 ± 0.54%
for BM-MSC andAD-MSC group, respectively).
Regulatory T cells
The results for AD-MSCs and BM-MSCs were grouped
for comparison because no significant differences were noted
in outcomes for individual dosages. Four weeks after trans-
plantation, there were 4.00 ± 1.04%Tregs in the control group
(Figure 7A-B). Significantly higher levels (8.28 ± 3.60%) were
only reached in the AD-MSC group (P < 0.01 vs. control). Af-
ter 6 weeks, Treg levels significantly dropped in the AD-MSC
and BM-MSC groups (P < 0.01 vs 4 weeks) and remained
lower at later time points as compared to 4 weeks, but higher
than that in all animals at 6 weeks, including those that were
prone to rejection.
Histopathology
Untreated controls (Figure 8E) showed histological signs
of acute rejection in hematoxylin-eosin–stained skin samples
and correlated with gross appearance found in vivo (clinical
FIGURE 5. Levels of peripheral blood chimerism 4 and 6 weeks af-
ter hindlimb transplantation and MSC administration (A). All controls
exhibited rejection at 6 weeks; therefore only data from week 4 are
available. All MSC-treated groups showed significant levels of chime-
rism based on the percentage of MHC class I antigen positive popu-
lation of all peripheral blood cells at 4 weeks. Yet this was only a
transient event and was completely abolished after 6 weeks. Repre-
sentative FACS image for peripheral blood chimerism based on class
I RT1Ac antigen at 4 and 6 weeks (B; 1  106 AD-MSC group).
(C) Further FACS analysis on RT1Ac+ cells revealed multi-lineage
chimerism based on CD11b/c/CD45R and CD4/CD8 antigens.
**P < 0.01 vs. control; ##P < 0.01 versus 4 weeks. FACS indicates
fluorescence-activated cell sorter.
FIGURE 6. Peripheral microchimerism in immunologically relevant
organs (inguinal lymph nodes, peripheral blood, thymus, spleen,
and bone marrow in transplanted [BM Tx] and contralateral hindlimb
[BM Cx]) based on class I RT1Ac antigen detected by FACS in ani-
mals with long-term allograft survival (>120 days). Although the levels
were below 1% in the peripheral blood and thymus in these end-
point experiments, intermediate (1-3%) and inconsistent levels were
found in inguinal lymph nodes on the allotransplant side. In spleen
and bone marrow of the allograft (i.e., tibial bone) levels ranged as
high as 3% to 5.5%. In the contralateral hindlimb, bone marrow
levels were around 3%.
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grade III). These included dense dermal, subdermal, and
perivascular infiltrates with epidermal and adnexal involve-
ment in terms of dyskeratosis, epithelial apoptosis as well as
keratinolysis. Moreover, we found infiltration of adnexae
with apoptosis and loss of architecture. Skin samples pro-
cured at end points from MSC-treated animals with long-
term surviving allografts (Figure 8A-D) showed minimal or
no signs of rejection in the histological assessment, regardless
of cell dosage, confirming clinical findings. Histopatholog-
ical grading per Banff criteria was limited to rare mild
perivascular infiltrates in some samples, with no involvement
of the overlying epidermal and adnexal structures.
DISCUSSION
This is the first direct comparison of the immunomodula-
tory effects of AD-MSCs and BM-MSCs in VCA.Our princi-
pal finding was that AD-MSCs and BM-MSCs, despite
differences in in vitro suppressor activity, demonstrated sim-
ilar immunologic efficacy and graft survival outcomes in vivo,
after single administration. Around 50% of animals showed
long-term allograft survival beyond 120 days afterMSC treat-
ment regardless of the source and dosage of cells. Our results
confirm that graft acceptance rather than tolerance was
achieved in treated recipients.
TheMSCs from adipose tissue and BM revealed similar sur-
face marker profiles, and were CD29hiCD73hiCD90hiCD45low,
which is a generally accepted panel for mesenchymal stem
cells.20 InMLR assays, MSCs strongly suppressed T-cell pro-
liferation in vitro. We were able to demonstrate in a head-to-
head comparison that AD-MSCs possess superior suppressor
potential than BM-MSCs. The BM-MSCs showed a dose-
dependent suppression of alloantigen-induced T-cell prolifer-
ation, whereas AD-MSCs were able to almost completely
abolish T-cell responses. The MLR assays with sPBMCs
demonstrated similar suppressive potentials with both MSC
types. These findings agree with recent reports in the
literature,21-23 but must be confirmed for human cells, where
dose-dependent suppression has been reported.24 The inher-
ent advantages of AD-MSCs, such as abundant fat tissue
availability, ease of retrieval, and smaller cell morphology
compared to BM-MSCs, support their role in clinical indica-
tions of relevance to AD-MSC therapies.25 Further studies in
preclinical models are required to establish the role and im-
pact of multiple variables related to cell dosing, timing, pas-
sage, and collateral effects of preparatory regimens.26,27
Long-term graft survival with survival greater than
120 days with no maintenance drug immunosuppression
was achieved in 47% of the treated animals. Histological
FIGURE 7. AD-MSCsandBM-MSCs inducedTregs (CD4
+CD25hiFoxP3+),
which at week 4 was significant only for the AD-MSC group (A). High
levels of Tregs were only transient and dropped significantly to lower
levels after 6 weeks. In animals showing prolonged graft survival,
we found slightly higher levels of Tregs compared to the 6-week time
point (including the animals with rejection). **P < 0.01 versus control;
#P < 0.05, ## P < 0.01 versus 4 weeks. (B) Representative FACS im-
age of an animal with increased Tregs levels (right) and corresponding
isotype control (left).
FIGURE 8. Histopathological findings in H&E-stained skin samples.
BM-MSC- (1  106 group [A] and 5  106 group [C]) and AD-MSC
(1  106 group [B] and 5  106 group [D]) treated long-term graft
accepting animals showed no or minimal histological signs of rejec-
tion. The epidermal and dermal layers were well preserved with nor-
mal dermal papillae; the adnexae showed normal architecture and
no infiltration. In few samples there was minimal perivascular infiltra-
tion. In MSC-untreated controls (E), we found keratinolysis and
dyskeratosis as well as epithelial cell apoptosis, with loss of dermal
papillae and an extensive infiltration throughout dermis and subder-
mis. Additionally, the adnexal structures showed inflammatory cell in-
filtration and apoptosis leading to architecture loss, which clinically
correlated with hair loss as typical for grade II rejection or higher.
10 magnification. Bar, 250 μm. H&E indicates hematoxylin-eosin.
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grading of skin samples per the Banff classification confirmed
rejection-free survival in all survivors.19 Allograft survival
may have been related to microchimerism in the BM and
lymphatic organs as demonstrated by flow cytometry analy-
sis, but this remains to be investigated further. We were not
able to confirm tolerance in survivors, as donor-specific skin
allografts were rejected in recipients with long-term hindlimb
survival and no evidence of persistent thymic chimerism was
observed, as reported to be a correlate or prerequisite for tol-
erance.28 In clinical trials of BM transplantation, MSCs have
been shown to facilitate hematopoietic stem cell engraftment
without graft-versus-host disease.29 In our study, donor cell
engraftment per MHC class I characterization was observed
not only in the transplanted limb but also in the contralateral
unoperated recipient limb. Hematopoietic stem cells from the
allograft BM may have engrafted into the recipient. It re-
mains unknown if MSCs may have facilitated this process
or engraft to lymphatic niches and modulate development
of donor chimerism in that specific compartment.
Despite the fact that AD-MSCs and BM-MSCs revealed
different immunosuppressive properties in vitro, the two cell
types did not differ significantly in terms of long-term graft
survival in vivo. Fundamental limitations of in vitro assays
preclude them from being accurate reflectors of in vivo be-
havior of cells. For in vitro MLR, proliferation of T cells (ei-
ther sorted or those in PBMC) in response to AD-MSCs and
BM-MSCs was evaluated under controlled culture and incu-
bation conditions. In contrast, the in vivo behavior of these
cells is impacted by diverse and dynamic interactions be-
tween cellular and humoral systems as well as the kinetics
of adaptive and innate immune phenomena. The in vivo envi-
ronment is thus indeed a stringent test bed for confirmation
of immunomodulatory efficacy. Our results indicate that nei-
ther variation of cell dosage nor cell type had a discernible ad-
vantage on long-term graft survival.
The MSC-based cell therapies have been studied in other
rodent and swine VCA models.30-32 Our experimental de-
sign in the current study was similar to that of Kuo et al,32
although a different immunosuppressant (cyclosporine A)
and 2 additional doses of AD-MSCs were administered,
and a higher long-term graft survival was achieved. We used
donor AD-MSCs in the current study. In contrast, Kuo et al,
evaluated syngeneic AD-MSCs in VCA.31 Their study sug-
gests that repetitive AD-MSC injections do not offer addi-
tional survival advantage in VCA.31 Regardless, a 66%
VCA survival rate was achieved with donor-specific toler-
ance developed by syngeneic AD-MSCs, which is superior
to that seen in our study with donor-derived cells. Immuno-
logic outcomes and survival differences among these 3 stud-
ies may be related to immunogenicity of allogeneic MSCs.
It is widely regarded that MSCs are immunoprivileged given
their low expression of MHC class I and II evidenced by sup-
pressor functions in vitro and in vivo.33-35 However, there
is also literature support for their capacity to induce alloanti-
bodies, CD8-mediated cytotoxicity, or rejection in allogeneic
settings.36-38Moreover, differentiation ofMSCs in vitro dur-
ing cell passagemay also alter their immunogenic behavior.39
Thus, cell longevity of allogeneic AD-MSCs may be different
from syngeneic cells in vivo. If we hypothesize that donor-
derived MSCs have a shorter in vivo lifespan, the benefits
of multiple dosing of such cells become more evident as
supported by the studies by Kuo et al32 versus the results
observed with single dose syngeneic AD-MSCs in VCA sur-
vival and tolerance.31
In our study, as in others, chimerism and Treg upregulation
were closely associated with prolongation of allograft sur-
vival.28,40-42 A pattern of significant, yet transient upreg-
ulation of Tregs after MSC treatment was seen in our study,
similar to that reported earlier by Kuo et al.43 Cheng et al31
achieved sustained circulating Treg levels in long-term allo-
graft surviving animals after the repetitive use of syngeneic
AD-MSCs. Treg induction has also been related to stable
tolerance in the pertinent literature. The exact difference
between syngeneic and allogeneic MSC in terms of immuno-
modulatory efficacy remains to be investigated.
Peripheral blood donor multilineage chimerismwas found
inMSC-treated recipients at an early stage (4weeks), but was
not maintained long term. However, investigation of lym-
phatic organs and BM revealed persistent donor micro-
chimerism in animals with long-term acceptance of allografts.
We interpret that sustained donor chimerism in various tissues
could contribute to VCA acceptance, even without the benefit
of sustained peripheral blood chimerism as found earlier by
Kuo et al.43 Chimerism may be an important requirement for
maintenance of allograft tolerance, as shown by various groups
in SOT.44-46
TheMSCs have been shown to home to sites of injury and
inflammation47,48 as well as to transplanted skin,49 whereas
other groups described cell entrapment in filtering organs
when injected systemically.50,51 In the present study, indeed,
we did not find any significant different outcome by increas-
ingMSC dosage 5-fold (1 106 vs 5 106 cells), which may
be related to the fact thatMSCs exert many of their beneficial
therapeutic effects through paracrine secretion overcoming
the constraints of entrapment.52,53 One of the primary limita-
tions of the current study is lack of evidence for the collateral
effect of immunosuppressive and lymphodepleting drugs on
MSC function in vivo. We believe that the choice of condi-
tioning and maintenance agents incorporated into transplant
regimens as well as the timing, dosing, and duration of such
treatments corresponding to or overlapping with cell-based
therapies may significantly influence viability and function
(proliferation, differentiation, homing, and engraftment) of
cellular components. The effect ofMSCs on functionalmotor
and sensory outcomes was outside the scope of the study but
should be addressed. These are all important research ques-
tions that must be systematically scrutinized in translational
VCA studies. Optimization of conventional immunosuppres-
sive regimens in VCA with MSC-based cell therapies war-
rants further investigation to improve safety, efficacy, and
quality of life outcomes of these promising procedures.
CONCLUSIONS
Taken together, immunosuppression-free long-term VCA
survival was achieved with both AD-MSCs and BM-MSCs.
Peripheral blood chimerism and Treg upregulation were only
transient events. Our in vivo findings did not reflect the supe-
rior immunomodulatory characteristics of AD-MSCs in vitro.
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